This Biotech Investor’s Picks Returned 31% in Q1; Here Are Its New Bets
Peter Kolchinsky is one of the best biotech investors and many of his stock picks generate strong returns.
Posts Tagged ‘Peter Kolchinsky’
Five Stocks To Buy According To Top Biotech-Focused Funds
Biotechnology is a very interesting industry to invest in, but also very complex.
Big Insider Buying at Hot IPO Solid Biosciences (SLDB), Range Resources (RRC) and General Electric (GE)
With the stock market having been battered in recent days and fears that a large correction may be starting to pick up steam becoming more pronounced, investors are now in a position...
Avexis Inc. (AVXS): RA Capital Management Ups Its Stake
Peter Kolchinsky's RA Capital Management has slightly raised its stake in Avexis Inc. (NASDAQ:AVXS), as per a new Form 13G with the Securities and Exchange Commission.
RA Capital Management Slashes Alcobra Ltd (ADHD) Position After FDA Clinical Hold
Peter Kolchinsky's RA Capital Management has slashed its position in Alcobra Ltd (NASDAQ:ADHD) to just under 1.31 million shares according to a new 13G filing with the SEC.
Aclaris Therapeutics Inc (ACRS): RA Capital Management Disposes of 1.1 Million Shares
An amended 13G filing with the SEC revealed that Peter Kolchinsky's RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics Inc (NASDAQ:ACRS), decreasing...
Protagonist Therapeutics Inc (PTGX): RA Capital Management Acquires 6.8% Stake
Peter Kolchinsky's RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently gone public, Protagonist...
RA Capital’s Top Q2 Performers; Predicts Big Things Ahead for Pharma Stocks
RA Capital Management LLC is a crossover fund manager that invests in public and private healthcare and life science companies developing drugs, medical devices and diagnostics...
Vitae Pharmaceuticals Inc (VTAE): RA Capital Management Ups Its Stake
A recent 13G filing with the SEC revealed that Peter Kolchinsky's RA Capital Management has acquired more shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE), as it currently...
Ardelyx (ARDX): RA Capital Management Boosts Stake to 7.7%
Peter Kolchinsky's RA Capital Management has stepped up its interest in Ardelyx Inc. (NASDAQ:ARDX).
Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE) & More Heading Into 2016
Peter Kolchinsky founded RA Capital Management in 2001 and focuses mainly on healthcare stocks.
Dalton Investments Proposes 6-Point Action Plan to Eros, While Eminence Capital Reveals New Stake in This Hotel Operator
The practice of monitoring quarterly 13F filings has become more popular in recent years, which led to several exchange traded funds (ETFs) being launched.
Two Activist Plays And Two Biotech Moves You Should Check Out
With hedge funds having submitted their 13F filings for the third quarter, people at Insider Monkey are busy compiling the data necessary to identify the best investment opportunities...
Is Zogenix A Good Stock To Buy Now?
RA Capital Management, led by Peter Kolchinsky, has disclosed a massive new stake in California-based pharmaceutical company Zogenix, Inc (NASDAQ:ZGNX).
Steve Cohen, Peter Kolchinsky Disclose New Stakes In Micro-cap Pharmaceutical Stocks
Steve Cohen’s Point72 Asset Management has initiated a new position in Inotek Pharmaceuticals Corporation (NASDAQ:ITEK).
Peter Kolchinsky’s New Top Healthcare Pick And Old Favorites
Peter Kolchinsky's RA Capital Management recently filed its 13F with the SEC for the reporting period of June 30.
RA Capital’s Latest Move In Alcobra Ltd (ADHD) Coming Off Hefty Second Quarter Gains
According to a recent filing with the Securities and Exchange Commission, Peter Kolchinsky's RA Capital has initiated a position in Alcobra Ltd (NASDAQ:ADHD), acquiring some 1...
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.
Ardelyx Inc (ARDX): RA Capital Management Discloses 7.3% Passive Stake
RA Capital Management, led by Peter Kolchinsky, has opened a new position in clinical-stage biopharmaceutical company Ardelyx Inc (NASDAQ:ARDX). A new filing with the U.S.
Bitauto Hldg Ltd (ADR) (BITA), Aurinia Pharmaceuticals Inc (AUPH): Tiger Global and RA Capital Disclose Their Latest Moves
In a new filing with the Securities and Exchange Commission, Billionaire Chase Coleman's Tiger Global disclosed slightly reducing its exposure to Bitauto Hldg Ltd (ADR) (NYSE...
Regulus Therapeutics Inc (RGLS), Trevena Inc (TRVN), Juno Therapeutics Inc (JUNO): RA Capital’s Top New Biotech Picks
Peter Kolchinsky’s RA Capital Management filed its latest 13F with the Securities and Exchange Commission in February, and we’ve gone through the data to highlight three of...
Tekmira Pharmaceuticals Corporation (TKMR): RA Capital Management Discloses 10% Passive Stake
It was revealed in a filing yesterday with the U.S Securities and Exchange Commission that RA Capital Management has opened a large, passive position in Tekmira Pharmaceuticals...
Seattle Genetics Inc. (SGEN), Cerus Corporation (CERS): Baker Bros. Advisors’ Latest Moves
Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday.
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James E. Flynn and Peter Kolchinsky Think These Stocks Look Healthy
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E.
Entegris Inc (ENTG), Dicerna Pharmaceuticals Inc (DRNA): GMT Capital and Deerfield Management Report Their Latest Moves
In two new filings, Thomas E. Claugus' GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG).
CIG Wireless Corp (CIGW), Achillion Pharmaceuticals Inc (ACHN): Jeffrey Tannenbaum And Peter Kolchinsky Disclose Their Latest Moves
CIG Wireless Corp (OTCBB:CIGW), an operator of wireless and broadcast communication towers in the United States, has issued approximately 1.25 million shares to Jeffrey Tannenbaum...
Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter Kolchinsky’s Latest Equity Moves
RA Capital Management has continued the sale of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares.
Achillion Pharmaceuticals, Inc. (ACHN): RA Capital Management Sells Over 2 Million Shares
RA Capital Management, managed by Peter Kolchinsky, continues to unload its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In a new filing with the U.S.
Sunesis Pharmaceuticals, Inc. (SNSS): Ken Griffin’s Citadel Boosts His Stake
Citadel Advisors, a fund managed by Ken Griffin, has disclosed boosting its stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).
Achillion Pharmaceuticals, Inc. (ACHN): Peter Kolchinsky’s RA Capital Sells Some More Shares
Peter Kolchinsky's RA Capital Management, in a new filing with the Securities and Exchange Commission, has disclosed the sale of around 1.70 million shares of Achillion Pharmaceuticals...
Hedge Fund News: Crispin Odey, Peter Kolchinsky & T Boone Pickens
Some of Europe's most powerful hedge fund managers are sharply divided on the outlook for English soccer club Manchester United PLC (NYSE:MANU) -0.17%, whose share price has ...
Achillion Pharmaceuticals Inc. (ACHN): RA Capital Management Cuts Stake To 19.0% From 21.1%
RA Capital Management, led by Peter Kolchinsky, disclosed in a newly amended filing with the U.S.
Cognizant Technology Solutions Corp (CTSH), Titan International Inc. (TWI), Salix Pharmaceuticals Ltd. (SLXP) Among Stocks Hedge Funds Are Bullish On
Amidst the 13F filing season, several hedge funds have also been filing Schedule 13G forms, disclosing changes that took place after June 30, 2014, in their equity positions.
RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc. (ACHN)
RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc.
James Litinsky is Bullish on Ophthotech Corp (OPHT); JHL Capital Boosts Stake in the Company
James H. Litinsky's JHL Capital Group has boosted its stake in Ophthotech Corp (NASDAQ:OPHT) to 1.78 million shares, a new filing with the SEC showed.
RA Capital Reports New 5.8% Position In Recently Public Versartis Inc (VSAR)
Peter Kolchinsky’s RA Capital Management has initiated a new position in Versartis Inc (NASDAQ:VSAR).
Ra Capital Management Reveals New Stake in Enanta Pharmaceuticals Inc (ENTA)
Peter Kolchinsky's Ra Capital Management disclosed a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
RA Capital Management Discloses New Stake in SANUWAVE Health Inc. (SNWV); Boosts Position in pSivida Corp. (PSDV)
In two recent filings with the U.S. Securities and Exchange Commission, Peter Kolchinsky’s RA Capital Management has revealed a new position in SANUWAVE Health Inc.
RA Capital Discloses New Passive Stake in Repros Therapeutics Inc (RPRX)
RA Capital Management, managed by Peter Kolchinsky, has revealed a new position in Repros Therapeutics Inc (NASDAQ:RPRX).
Baker Bros. Advisors’ Latest Moves Involve ACADIA Pharmaceuticals Inc. (ACAD) & Synageva Biopharma Corp (TRMS)
Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc.
Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside
Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million shares of Dicerna ...
Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped
Peter Kolchinsky's Ra Capital Management, has just disclosed initiating a 7.2% stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX).
Tang Capital Management Is Getting Out of OncoGenex Pharmaceuticals Inc (OGXI) and Cyclacel Pharmaceuticals Inc (CYCC)
Kevin C. Tang's Tang Capital Management has decreased its position it two pharmaceutical companies.
Hedge Fund News: Jamie Zimmerman, Perry Capital & Paul Singer
Women hedge fund managers have outperformed their male rivals, on average, for the second year in a row, according to professional services firm Rothstein Kass which tracks the...
Ra Capital Management Lowers Stake in Derma Sciences Inc (DSCI)
Peter Kolchinsky's Ra Capital Management has recently sold a total of 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI).
5 Stocks Hedge Funds Bought Recently
Academic research on hedge funds have shown that the stocks bought by hedge funds outperform the market on average.
Peter Kolchinsky, Ra Capital Management Inrease Stake in Achillion Pharmaceuticals Again
Peter Kolchinsky's hedge fund, Ra Capital Management disclosed upping its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) some more.
Peter Kolchinsky, Ra Capital Buy More Achillion Pharmaceuticals at $2.48/Share
Peter Kolchinsky's, RA Capital Management solidified its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) even more today.
Peter Kolchinsky’s RA Capital Has Been Very Active This Month
Since the beginning of November, Peter Kolchinsky's RA Capital Management has informed the U.S.
